Dr. Reddy's Laboratories Revenue, Profits - RDY Quarterly Income Statement

Add to My Stocks
$33.16 $0.9 (2.64%) RDY stock closing price Mar 16, 2018 (Closing)

Fundamental analysis of RDY stock involves analyzing its financial statements, apart from checking the Dr. Reddy's Laboratories stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. Like any other income statement, the RDY income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue growth of 9.76% when compared to the same period in the past. One also needs to look at Dr. Reddy's Laboratories assets, operating expenses and Dr. Reddy's Laboratories free cash flow. The Dr. Reddy's Laboratories profit and loss statement shows revenue of $596M for 2018 Q3. Revenue has grown by 9.76% QoQ for RDY stock.

View and download details of revenue and profits for Dr. Reddy's Laboratories for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Apr - Mar2018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q2
Dr. Reddy's Laboratories Revenues or Net Sales
Cost Of Goods Sold (COGS)258.06M258.32M249M293.31M223.29M236.4M210M229.97M244.55M237.48M
Dr. Reddy's Laboratories Gross Profit
Research & Development Expense72.34M65.13M79M78.83M72.96M78.21M71M68.88M62.24M68.88M
Selling General & Admin Expense181.89M170.32M179M181.33M164.22M172.45M181M159.51M181.13M165.36M
Income Before Depreciation Depletion Amortization77.64M59.4M6M54.99M85.23M50.78M17M68.27M115.18M142.55M
Depreciation Depletion Amortization----------
Non Operating Income17.64M4.53M9M5.86M4.52M8.62M10M13.18M6.99M6.83M
Interest Expense3.13M3.47M3M5.55M2.56M1.89M2M52.76M6.96M9.28M
Dr. Reddy's Laboratories Pretax Income
Provision for Income Taxes40.32M16.02M3M1.76M17.97M13.27M7M24.88M27.17M28.95M
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations52M44M9M48M69M44M18.88M11M88M110M
Extraordinary Items & Discontinued Operations----------
Dr. Reddy's Laboratories Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS162.5M169.23M150M165.52M164.29M162.96M169.53M157.14M172.55M171.88M
Average Shares used to compute Basic EPS162.5M169.23M150M165.52M164.29M162.96M169.53M157.14M172.55M171.88M
Income Before Nonrecurring Items66.57M44M9M48M69M44M18.88M11M88M110M
Income from Nonrecurring Items-14.57M---------
Dr. Reddy's Laboratories Earnings Per Share Basic Net
Dr. Reddy's Laboratories Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items0.410.
Preferred Dividends Acc Pd----------
Dividends Common0.0048.76--------
Dividend Per Share Common-
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

It is very helpful to read a report on Dr. Reddy's Laboratories stock analysis. An investor must check the following items in an income statement:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Dr. Reddy's Laboratories revenue chart, implies that the company is growing. It has been the case with Dr. Reddy's Laboratories. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. RDY stock had a healthy bottom line growth.

The income statement is also called the profit and loss statement. Apart from the RDY income statement, one can check the Dr. Reddy's Laboratories historical stock prices to check how the price has moved with time.

Dr. Reddy's Laboratories Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
PS Ratio (price sales ratio)
Operating Margin
Net Profit Margin
Dividend Yield

Other Income Statements - Dr.Reddy's Laboratories Ltd (ADR) Industry Peers

Novartis income statement, Sanofi income statement, Teva Pharmaceutical income statement